

Supplementary Table 1. Analysis of CMV-related costs in D+/R- subgroup.

	Ganciclovir n= 5	Valacyclovir n=8	Preemptive n=6	Deferred n=1	P ^a
Total CMV related costs (mean ± SD)	3680 ± 1986	2354 ± 493	12094 ± 8561	23163	<0.05 ^b
Median	2986	2266	13364		

^aKruskal-Wallis One way ANOVA on ranks. Costs in EUR 2010.

^bMultiple pairwise comparison showed significant difference in valacyclovir group when compared to preemptive therapy.

Supplementary Table 2. Analysis of CMV-related costs in moderate risk (D+/R+ and D-/R+) subgroup.

	Ganciclovir n= 30	Valacyclovir n=59	Preemptive n=30	Deferred n=11	P ^a
Total CMV related expenses in EUR (mean ± SD)	4699 ± 3101	2590 ± 3822	3496 ± 1433	6616 ± 4417	<0.05 ^b
Median	4208	2012	2960	6286	

^aKruskal-Wallis One way ANOVA on ranks. Costs in EUR 2010.

^bMultiple pairwise comparison showed significant difference in valacyclovir group when compared to any other regimen (p < 0.05).